Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FWUVN
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,715
Award facts
- Contract value 100% obligated
- $22,714.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,714.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injectors. The contract, which became effective on August 8, 2025, with an ultimate completion date of August 11, 2025, carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with DLA valued at $499,999,999 through the SPE2DB program, which enables the agency to procure a comprehensive range of pharmaceutical products to support medical supply requirements across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, maintaining a robust portfolio of delivery orders for diverse medical products ranging from specialty medications and oncology treatments to vaccines and medical consumables. The company's consistent success in securing contracts with DLA reflects its capability to deliver branded and generic prescription drugs, biologics, and medical supplies to military and federal healthcare systems on a nationwide basis. This particular delivery order for Nucala auto-injectors—a biologic treatment typically used for severe eosinophilic asthma and other conditions—exemplifies the company's role in ensuring that Department of Defense personnel have access to critical pharmaceutical therapies.
Quick answers
Who was awarded contract SPE2DB25FWUVN?
SPE2DB25FWUVN was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 8, 2025.
How much is contract SPE2DB25FWUVN worth?
The government has obligated $22,715 on SPE2DB25FWUVN.
Is contract SPE2DB25FWUVN an order under another contract?
Yes. SPE2DB25FWUVN is a delivery order under SPE2DB25D9312, an indefinite delivery contract.
Was contract SPE2DB25FWUVN competed?
The extent of competition for SPE2DB25FWUVN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award